RHYTHM PHARMACEUTICALS, INC. (RYTM)
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
📈 **POSITIVE** • High confidence analysis (80%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (90%) **Content type:** Clinical